Venus Williams' Returns To Tennis For The Health Insurance Coverage
Venus Williams' return to tennis draws attention to the high costs of COBRA health insurance and broader U.S. challenges with medical debt and health care affordability.
Venus Williams' return to tennis draws attention to the high costs of COBRA health insurance and broader U.S. challenges with medical debt and health care affordability.
UnitedHealth Group is cooperating with federal investigations into its Medicare Advantage billing practices amid scrutiny over diagnosis-based payments. The insurer faces civil and criminal probes amid increased healthcare utilization and financial pressure.
Tennessee risks significant health insurance coverage losses and premium increases without extension of enhanced premium tax credits established by the American Rescue Plan, impacting over 265,000 residents and rural healthcare providers.
U.S. health insurers face financial pressures from rising Medicare Advantage costs, increased healthcare utilization, and regulatory debates over physician payments and drug pricing, impacting premiums and provider networks.
ACA health insurance premiums face significant hikes in 2026 due to rising healthcare costs and expiration of federal subsidies, impacting millions of enrollees.
ACA premium increases projected as key subsidies expire at the end of 2025, driving the largest cost hike in five years and affecting millions of enrollees.
Tennessee ACA health insurance premiums are set to increase by 15% in 2026 due to the expiration of tax credits and rising medical costs, affecting both marketplace and employer-sponsored plans.
Tennessee's ACA health insurance premiums are set to rise by 15% in 2026 due to expiring tax credits and rising medical costs. Learn about the regulatory changes and impact on employer-sponsored insurance.
Cigna Group navigates rising medical costs, specialty drug expenses, and mixed trading signals as analysts maintain a positive outlook amid sector-wide challenges.
Analysis shows a 25% increase in U.S. private insurer prescription drug denials from 2016-2023, driven by rising drug costs and claim automation. Insights into industry impact and reform efforts.